Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
5 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
Yesterday
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.

Atrial fibrillation strongly predicts stroke in males

16 Nov 2018

Atrial fibrillation appears to be the strongest determinant of stroke over 48 years of follow-up in males, a study has found.

The study followed 854 men from the age of 50 to 98 years. All participants underwent repeated medical examinations and completed lifestyle questionnaires.

Cox proportional hazards analysis revealed several determinants of ischaemic stroke, as follows: atrial fibrillation (hazard ratio [HR], 6.61; 95 percent CI, 4.47–9.77), mother dead from cardiovascular disease (HR, 1.53; 1.09–2.17), high education (HR, 0.81; 0.69–0.96) and increased physical activity level during leisure time (HR, 0.68; 0.50–0.93).

Meanwhile, haemorrhagic stroke risk was associated with heart rate (HR, 1.04; 1.01–1.06) and mother dead from stroke (HR, 3.56; 1.43–8.87).

Significant factors associated with all stroke included atrial fibrillation (HR, 5.34; 3.68–7.75), high diastolic blood pressure (HR, 1.02; 1.01–1.03), increased body weight (HR, 0.96; 0.94–0.99), high educational level (HR, 0.79; 0.68–0.92), wide waist circumference (HR, 1.04; 1.01–1.07), smoking (HR, 1.25; 1.06–1.48), mother dead from cerebrovascular disease (HR, 1.43; 1.05–1.94) and diabetes mellitus (HR, 1.65; 1.02–2.68).

Notably, stroke occurred in 88 percent of men diagnosed with atrial fibrillation.

The findings underscore a need for improved prophylaxis through intense treatment of modifiable determinants, researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
5 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
Yesterday
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.